Tremendous buzz led up to the June 7, 2021 announcement that the U.S. Food and Drug Administration (FDA) approved aducanumab, Biogen’s drug for Alzheimer’s disease. Aducanumab, marketed as AduhelmTM, is the first drug for the disease-modifying treatment of this condition. It has been 17 years since the last breakthrough in Alzheimer’s disease treatment.
The reviews are mixed. Many suggest this is a new era of hope for the Alzheimer’s disease community.
“This will give us a new biological foothold to build on,” said Stephen Salloway, Director of Neurology at Butler Hospital and professor at Brown University.
“It will take more advances, but it does appear from the science that people, especially at early stages, could be real beneficiaries and that the benefits accumulate over time,” said Harry Johns, President and Chief Executive of the Alzheimer’s Association.
On the other end of the spectrum, the Institute for Clinical and Economic Review (ICER) found aducanumab’s price does not align with clinical benefits. Given the risk of side effects and the uncertainty of benefit, ICER assigned a draft rating of “insufficient” to the strength of evidence on whether aducanumab provides a net health benefit for patients.
For additional information on the clinical and financial implications as the Alzheimer’s disease community adopts this new drug, contact your PSG contact or reach out to be connected to a pharmacy expert.